In November they raised the hope of a dividend at the full yesr. Interesting that they have not repeated it here.
Results OK, efficiency initiatives good, Health Solutions good, but they need to reverse constant revenue decline in rest of business.
Little downside at NAV. Jury still out on upside. On balance, I think it’s a good medium term buy.
